Pag. 31-35 [prev][index][next]
Second line treatment for relapsed chronic lymphocytic leukemia
Giuseppe Rossi
Divisione di Ematologia, Spedali Civili, Brescia, Italy
In spite of the remarkable therapeutic achievements obtained with purine analogues and monoclonal antibodies, chronic lymphatic leukaemia (CLL) has still to be considered an incurable disease. Indeed, in the vast majority of patients, the natural history of the disease is characterized by multiple relapses and by multiple remissions, induced by the potential treatments available.